Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
5,131,323
-
Share change
-
-493,493
-
Total reported value
-
$16,931,897
-
Put/Call ratio
-
64%
-
Price per share
-
$3.30
-
Number of holders
-
48
-
Value change
-
-$1,754,628
-
Number of buys
-
13
-
Number of sells
-
33
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q3 2021
As of 30 Sep 2021,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,131,323 shares.
The largest 10 holders included
VANGUARD GROUP INC, SABBY MANAGEMENT, LLC, BlackRock Inc., JPMORGAN CHASE & CO, Ikarian Capital, LLC, GEODE CAPITAL MANAGEMENT, LLC, ABNER HERRMAN & BROCK LLC, RAYMOND JAMES & ASSOCIATES, GSA CAPITAL PARTNERS LLP, and MILLENNIUM MANAGEMENT LLC.
This page lists
48
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.